Hepatology & Liver Disease

Hepatology in 2027 is defined by the first FDA-approved MASH therapy — resmetirom (THR-beta agonist) following MAESTRO-NASH — and the rapid expansion of GLP-1 and dual agonists (semaglutide ESSENCE, survodutide, tirzepatide) into metabolic liver disease. HCV elimination programs are being benchmarked against WHO 2030 targets, while HBV functional cure pipelines (siRNA bepirovirsen, capsid assembly modulators) advance through phase 3. The track also covers BAVENO VII portal hypertension, normothermic machine perfusion expanding the DCD donor pool, and acute-on-chronic liver failure stratification.